Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Key Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

        4.1.1. Global GDP Growth Outlook

        4.1.2. Global Healthcare Expenditure Outlook

    4.2. Forecast Factors - Relevance & Impact

        4.2.1. Number of Patients undergoing Therapy

        4.2.2. Number of Sittings

        4.2.3. Measures Prescribed for Treatment

        4.2.4. Timeframe of treatment

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis

    5.1. Current COVID19 Statistics and Probable Future Impact

    5.2. Current GDP Projection and Probable Impact

    5.3. COVID19 and Impact Analysis, by Country 

    5.4. 2020 Market Scenario

6. Key Success Factors

    6.1. Pipeline assessment

    6.2. Key Regulatory Scenario

7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031

    7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Form 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn)  By Form, 2016-2020

    8.3. Current and Future Market Size (US$ Mn)  Analysis and Forecast By Form, 2021-2031

        8.3.1. CIVN Injectable

        8.3.2. Oral

        8.3.3. Transdermal Patches

    8.4.  Market Attractiveness Analysis By Form

9. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Drug Class 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn)  Analysis By Drug Class, 2016-2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2021-2031

        9.3.1. 5-HT3 Receptor Antagonists

        9.3.2. Neurokinin-1 Receptor Antagonists

        9.3.3. Corticosteroids

        9.3.4. Cannabinoids

        9.3.5. Others

    9.4. Market Attractiveness Analysis By Drug Class 

10. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Emetogenic Risk

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn)  Analysis By Emetogenic Risk, 2016-2020

    10.3. Current and Future Market Size (US$ Mn)  Analysis and Forecast By Emetogenic Risk, 2021-2031

        10.3.1. Highly Emetogenic Chemotherapy (HEC)

        10.3.2. Moderately Emetogenic Chemotherapy (MEC)

        10.3.3. Low Emetogenic Chemotherapy (LEC)

    10.4. Market Attractiveness Analysis By Emetogenic Risk

11. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031

        11.3.1. Hospital

        11.3.2. Cancer Research Institute

        11.3.3. Retail Pharmacies

        11.3.4. Online Pharmacies

        11.3.5. Drug Stores

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis  By Region, 2016-2020

    12.3. Current Market Size (US$ Mn) Analysis and Forecast  By Region, 2021-2031

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. South Asia

        12.3.5. East Asia

        12.3.6. Oceania

        12.3.7. MEA

    12.4. Market Attractiveness Analysis By Region

13. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn)  Trend Analysis By Market Taxonomy, 2016-2020

    13.3. Market Size (US$ Mn)  Forecast By Market Taxonomy, 2021-2031

        13.3.1.  By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Form

        13.3.3. By Drug Class

        13.3.4. By Emetogenic Risk

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

14. Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn)  Trend Analysis By Market Taxonomy, 2016-2020

    14.3. Market Size (US$ Mn)  Forecast By Market Taxonomy, 2021-2031

        14.3.1.  By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin america

        14.3.2. By Form

        14.3.3. By Drug Class

        14.3.4. By Emetogenic Risk

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

15. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn)  Trend Analysis  By Market Taxonomy, 2016-2020

    15.3. Market Size (US$ Mn)  Forecast By Market Taxonomy2021-2031

        15.3.1.  By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Form

        15.3.3. By Drug Class

        15.3.4. By Emetogenic Risk

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

16. South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn)  Trend Analysis  By Market Taxonomy, 2016-2020

    16.3. Market Size (US$ Mn)  Forecast By Market Taxonomy2021-2031

        16.3.1.  By Country

            16.3.1.1. India

            16.3.1.2. Malaysia

            16.3.1.3. Indonesia

            16.3.1.4. Rest of South Asia

        16.3.2. By Form

        16.3.3. By Drug Class

        16.3.4. By Emetogenic Risk

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

17. East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn)  Trend Analysis  By Market Taxonomy, 2016-2020

    17.3. Market Size (US$ Mn)  Forecast By Market Taxonomy2021-2031

        17.3.1.  By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South korea

        17.3.2. By Form

        17.3.3. By Drug Class

        17.3.4. By Emetogenic Risk

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

18. Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn)  Trend Analysis  By Market Taxonomy, 2016-2020

    18.3. Market Size (US$ Mn)  Forecast By Market Taxonomy2021-2031

        18.3.1.  By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Form

        18.3.3. By Drug Class

        18.3.4. By Emetogenic Risk

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

19. MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn)  Trend Analysis  By Market Taxonomy, 2016-2020

    19.3. Market Size (US$ Mn)  Forecast By Market Taxonomy2021-2031

        19.3.1.  By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. Rest of MEA

        19.3.2. By Form

        19.3.3. By Drug Class

        19.3.4. By Emetogenic Risk

        19.3.5. By Distribution Channel

    19.4. Market Attractiveness Analysis

20. Emerging Countries Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis 2016-2020 and Forecast 2021-2031

    20.1. Introduction

        20.1.1. Market Value Proportion Analysis, By Key Countries

        20.1.2. Global Vs. Country Growth Comparison

    20.2. U.S. Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.2.1. By Form

        20.2.2. By Drug Class

        20.2.3. By Emetogenic Risk

        20.2.4. By Distribution Channel

    20.3. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.3.1. By Form

        20.3.2. By Drug Class

        20.3.3. By Emetogenic Risk

        20.3.4. By Distribution Channel

    20.4. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.4.1. By Form

        20.4.2. By Drug Class

        20.4.3. By Emetogenic Risk

        20.4.4. By Distribution Channel

    20.5. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.5.1. By Form

        20.5.2. By Drug Class

        20.5.3. By Emetogenic Risk

        20.5.4. By Distribution Channel

    20.6. U.K. Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.6.1. By Form

        20.6.2. By Drug Class

        20.6.3. By Emetogenic Risk

        20.6.4. By Distribution Channel

    20.7. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.7.1. By Form

        20.7.2. By Drug Class

        20.7.3. By Emetogenic Risk

        20.7.4. By Distribution Channel

    20.8. France Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.8.1. By Form

        20.8.2. By Drug Class

        20.8.3. By Emetogenic Risk

        20.8.4. By Distribution Channel

    20.9. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.9.1. By Form

        20.9.2. By Drug Class

        20.9.3. By Emetogenic Risk

        20.9.4. By Distribution Channel

    20.10. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.10.1. By Form

        20.10.2. By Drug Class

        20.10.3. By Emetogenic Risk

        20.10.4. By Distribution Channel

    20.11. BENELUX Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.11.1. By Form

        20.11.2. By Drug Class

        20.11.3. By Emetogenic Risk

        20.11.4. By Distribution Channel

    20.12. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.12.1. By Form

        20.12.2. By Drug Class

        20.12.3. By Emetogenic Risk

        20.12.4. By Distribution Channel

    20.13. China Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.13.1. By Form

        20.13.2. By Drug Class

        20.13.3. By Emetogenic Risk

        20.13.4. By Distribution Channel

    20.14. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.14.1. By Form

        20.14.2. By Drug Class

        20.14.3. By Emetogenic Risk

        20.14.4. By Distribution Channel

    20.15. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.15.1. By Form

        20.15.2. By Drug Class

        20.15.3. By Emetogenic Risk

        20.15.4. By Distribution Channel

    20.16. India Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.16.1. By Form

        20.16.2. By Drug Class

        20.16.3. By Emetogenic Risk

        20.16.4. By Distribution Channel

    20.17. Malaysia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.17.1. By Form

        20.17.2. By Drug Class

        20.17.3. By Emetogenic Risk

        20.17.4. By Distribution Channel

    20.18. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.18.1. By Form

        20.18.2. By Drug Class

        20.18.3. By Emetogenic Risk

        20.18.4. By Distribution Channel

    20.19. New Zealand Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.19.1. By Form

        20.19.2. By Drug Class

        20.19.3. By Emetogenic Risk

        20.19.4. By Distribution Channel

    20.20. GCC Countries Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.20.1. By Form

        20.20.2. By Drug Class

        20.20.3. By Emetogenic Risk

        20.20.4. By Distribution Channel

    20.21. Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.21.1. By Form

        20.21.2. By Drug Class

        20.21.3. By Emetogenic Risk

        20.21.4. By Distribution Channel

    20.22. South Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Analysis

        20.22.1. By Form

        20.22.2. By Drug Class

        20.22.3. By Emetogenic Risk

        20.22.4. By Distribution Channel

21. Market Structure Analysis

    21.1. Market Analysis by Tier of Companies 

    21.2. Market Concentration

    21.3. Market Share Analysis of Top Players

22. Competition Analysis

    22.1. Competition Dashboard

    22.2. Competition Deep Dive 

        22.2.1. Kyowa Kirin, Inc.

            22.2.1.1. Overview

            22.2.1.2. Product Portfolio

            22.2.1.3. Sales Footprint

            22.2.1.4. Strategy Overview

                22.2.1.4.1. Marketing Strategy

                22.2.1.4.2. Product Strategy

                22.2.1.4.3. Channel Strategy

        22.2.2. Pfizer Inc.

            22.2.2.1. Overview

            22.2.2.2. Product Portfolio

            22.2.2.3. Sales Footprint

            22.2.2.4. Strategy Overview

                22.2.2.4.1. Marketing Strategy

                22.2.2.4.2. Product Strategy

                22.2.2.4.3. Channel Strategy

        22.2.3. GlaxoSmithKline plc.

            22.2.3.1. Overview

            22.2.3.2. Product Portfolio

            22.2.3.3. Sales Footprint

            22.2.3.4. Strategy Overview

                22.2.3.4.1. Marketing Strategy

                22.2.3.4.2. Product Strategy

                22.2.3.4.3. Channel Strategy

        22.2.4. AbbVie Inc. (Allergan plc)

            22.2.4.1. Overview

            22.2.4.2. Product Portfolio

            22.2.4.3. Sales Footprint

            22.2.4.4. Strategy Overview

                22.2.4.4.1. Marketing Strategy

                22.2.4.4.2. Product Strategy

                22.2.4.4.3. Channel Strategy

        22.2.5. Merck & Co., Inc.

            22.2.5.1. Overview

            22.2.5.2. Product Portfolio

            22.2.5.3. Sales Footprint

            22.2.5.4. Strategy Overview

                22.2.5.4.1. Marketing Strategy

                22.2.5.4.2. Product Strategy

                22.2.5.4.3. Channel Strategy

        22.2.6. Bausch Health Companies Inc.

            22.2.6.1. Overview

            22.2.6.2. Product Portfolio

            22.2.6.3. Sales Footprint

            22.2.6.4. Strategy Overview

                22.2.6.4.1. Marketing Strategy

                22.2.6.4.2. Product Strategy

                22.2.6.4.3. Channel Strategy

        22.2.7. Novartis AG

            22.2.7.1. Overview

            22.2.7.2. Product Portfolio

            22.2.7.3. Sales Footprint

            22.2.7.4. Strategy Overview

                22.2.7.4.1. Marketing Strategy

                22.2.7.4.2. Product Strategy

                22.2.7.4.3. Channel Strategy

        22.2.8. Ono Pharmaceutical Co., Ltd.

            22.2.8.1. Overview

            22.2.8.2. Product Portfolio

            22.2.8.3. Sales Footprint

            22.2.8.4. Strategy Overview

                22.2.8.4.1. Marketing Strategy

                22.2.8.4.2. Product Strategy

                22.2.8.4.3. Channel Strategy

        22.2.9. Camurus AB

            22.2.9.1. Overview

            22.2.9.2. Product Portfolio

            22.2.9.3. Sales Footprint

            22.2.9.4. Strategy Overview

                22.2.9.4.1. Marketing Strategy

                22.2.9.4.2. Product Strategy

                22.2.9.4.3. Channel Strategy

        22.2.10. Heron Therapeutics, Inc.

            22.2.10.1. Overview

            22.2.10.2. Product Portfolio

            22.2.10.3. Sales Footprint

            22.2.10.4. Strategy Overview

                22.2.10.4.1. Marketing Strategy

                22.2.10.4.2. Product Strategy

                22.2.10.4.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology

List Of Table

Table 01 : Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form 

Table 02: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 03: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenik Risk

Table 04: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 05: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Region

Table 06: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 07: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 08: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 09: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 10: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 11: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 12: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 13: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 14: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 15: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 16: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 17: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 18: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 19: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 20: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 21: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 22: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 23: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 24: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 25: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 26: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 27: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 28: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 29: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 30: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 31: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 32: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 33: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 34: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 35: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 36: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Forecast 2016–2031, By Country

Table 37: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Form

Table 38: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Class

Table 39: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Emetogenic Risk

Table 40: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

List Of Figures

Figure 01: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 02: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 03: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Absolute $ Opportunity, 2021 - 2031

Figure 04: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Share Analysis (%),By Form, 2021-2031

Figure 05: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Y-o-Y Analysis (%), By Form, 2021-2031

Figure 06: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis By Form, 2021-2031

Figure 07: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Share Analysis (%), By Drug Class, 2021-2031

Figure 08: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Y-o-Y Analysis (%), By Drug Class, 2021-2031

Figure 09: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis By Drug Class, 2021-2031

Figure 10: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Share Analysis (%), By Emetogenik Risk, 2021-2031

Figure 11: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Y-o-Y Analysis (%), By Emetogenik Risk, 2021-2031

Figure 12: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis By Emetogenik Risk, 2021-2031

Figure 13: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Share Analysis (%), By Distribution Channel, 2021-2031

Figure 14: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Y-o-Y Analysis (%), By Distribution Channel, 2021-2031

Figure 15: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 16: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Share Analysis (%), By Region, 2021-2031

Figure 17: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Y-o-Y Analysis (%), By Region, 2021-2031

Figure 18: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Region, 2021-2031

Figure 19: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 20: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 21: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 22: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 23: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 24: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 25: North America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 26: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 27: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 28: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 29: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 30: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 31: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 32: Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 33: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 34: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 35: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 36: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 37: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 38: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 39: Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 40: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 41: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 42: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 43: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 44: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 45: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 46: South Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 47: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 48: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 49: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 50: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 51: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 52: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 53: East Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 54: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 55: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 56: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 57: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 58: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 59: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 60: Oceania Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031

Figure 61: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Analysis (US$ Mn), 2016-2020

Figure 62: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Value Forecast (US$ Mn), 2021-2031

Figure 63: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Form, 2021-2031

Figure 64: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Drug Class, 2021-2031

Figure 65: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Emetogenic Risk, 2021-2031

Figure 66: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 67: MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Attractiveness Analysis by Country, 2021-2031